The role of inflammation in Lymphoma

Advances in Experimental Medicine and Biology

Volumn 816, Issue , 2014, Pages 315-333

  Carbone, Antonino ^a   Tripodo, Claudio ^b   Carlo Stella, Carmelo ^c   Santoro, Armando ^c   Gloghini, Annunziata ^d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; LENALIDOMIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHRONIC INFLAMMATION; CLASSICAL HODGKIN LYMPHOMA; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; FOLLICULAR LYMPHOMA; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL; LYMPHOMATOID GRANULOMATOSIS; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PATHOGENESIS; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; B CELL LYMPHOMA; CARCINOGENESIS; HEPATITIS C; HODGKIN DISEASE; LYMPH NODE; LYMPHOID ORGAN;

EID: 84959231815     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-348-837-8_12     Document Type: Article

References (93)

1. Aldinucci D, Lorenzon D, Cattaruz za L, Pinto A, Gloghini A, Carbone A, Colombatti (2008) Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/RANTES in tumour cell growth and microenvironmental interactions. I nt J Cancer 122(4):769-776
2. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A (2010) The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 221(3):248-263
3. Aldinucci D, Celegato M, Borghese C, Colombatti A, Carbone A (2011) IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br J Haemato l 152(2):182-190
4. Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, Fujii N et al (2004) Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 5(9):943-952
5. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD et al (2000) A chemokinedriven positive feedback loop organizes lymphoid follicles. Nature 406(6793):309-314
6. Aozasa K ( 2006) Pyothorax-associated lymphoma. J Clin Exp Hematop 46(1):5-10
7. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B cell malignancies: a target for ne w treatment strategies. Blood 114(16):3367-3375
8. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, Xerri L (2008 ) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26(3):440-446. doi:10.1200/JCO.2007. 12.8298
9. Carbone A, Manconi R, Poletti A, Volpe R (1985) Practical importance of immunostaining paraffin-embedded biopsy samples of small lymphocytic and follicle centre cell lymphomas for S100 protein. Lancet 2(8455):617
10. Carbone A, Gloghini A, Gruss HJ, Pinto A (1995) CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 147(4):912-922
11. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G (2002) Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 117(2):366-372
12. Carbone A, Gloghini A, Cabras A, Elia G (2009) The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol 145(4):468-480
13. Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E (2009) High numb ers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 27(9):1470-1476. doi:10.1200/JCO.2008.18.0513
14. Ch eung KJ, Johnson NA, Affleck JG, Severson T, Steidl C, Ben-Neriah S et al (2010) Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 70(22):9166-9174
15. Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG (2008) Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother 31(2):132-147. doi:10.1097/CJI.0b013e31815b69c8
16. Coupland SE (2011) The challenge of the microenvironment in B-cell lymphomas. Histopathology 58(1):69-80. doi:10.1111/j.1365-2559.2010.03706.x
17. Dammacco F, Gatti P, Sansonno D (1998) Hepatitis C virus infection, mixed cryoglobulinemia, and non-Hodgkin's lymphoma: an emerging picture. Leuk Lymphoma 31(5-6):463-476
18. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351(21):2159-2169
19. de Jong D, Fest T (2011) The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 24(2):135-146. doi:10.1016/j.beha.2011.02.007. (Epub 2011 May 17
20. De Vita S, Sansonno D, Dolcetti R, Ferraccioli G, Carbone A, Cornacchiulo V et al (1995) Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood 86(5): 1887-1892
21. Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B et al (2006) Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30(4):490-494
22. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD (2005) Analysis of multiple biomarkers shows that lymphomaassociated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106(6):2169-2174. doi :10.1182/blood-2005-04-1565
23. Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, Gascoyne RD (2010) Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 95(12):2157-2160. doi:10.3324/haematol.2009. 021766
24. Fukayama M, Ibuka T, Hayashi Y, Ooba T, Koike M, Mizutani S (1993) Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol 143(4):1044-1049
25. Gascoyne RD, Steidl C (2011) VII. The role of the microenvironment in lymphoid cancers. Ann Oncol 22 (Suppl 4):iv47-iv50. doi:10.1093/annonc/mdr173
26. Germanidis G, Haioun C, Dhumeaux D, Reyes F, Pawlotsky JM (1999) Hepatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma. Hepatology 30(3):822-823
27. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23(2):249-262. doi:10.1016/j.ccr.2013.01.008
28. Gloghini A, Carbone A (1993) The nonlymphoid microenvironment of reactive follicles and lymphomas of follicular origin as defined by immunohistology on paraffin-embedded tissues. Hum Pathol 24(1): 67-76
29. Gloghini A, Volpe R, Carbone A (1990) Vimentin immunostaining in fibroblastic reticulum cells within human reactive and neoplastic lymphoid follicles. Hum Pathol 21(8):792-798
30. Hopken UE, Rehm A (2012) Homeostatic chemokines guide lymphoma cells to tumor growthpromoting niches within secondary lymphoid organs. J Mol Med 90(11):1237-1245
31. Husson H, Freedman AS, Cardoso AA, Schultze J, Munoz O, Strola G et al (2002) CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br J Haematol 119(2):492-495
32. IARC (2012) Monographs on the evaluation of carcinogenic risks to humans. In: ARC monographs on the evaluation of carcinogenic risks to humans, vol 100B. Biological Agents, Lyon, France
33. Iqbal J, Weisenburger DD, Grein er TC, Vose JM, McKeithan T, Kucuk C et al (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115(5):1026-1036
34. Jaffe ES, Wilson WH (1997) Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv 30:233-248
35. Klein U, Dalla-Favera R (2008) Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 8(1):22-33
36. Koster A, van Krieken JH, Mackenzie MA, Schraders M, Borm GF, van der Laak JA, Leenders W, Hebeda K, Raemaekers JM (2005) Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 11(1):154-161
37. Kraus MD, Haley J (2000) Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis. Am J Surg Pathol 24(8):1068-1078
38. Kridel R, Sehn LH, Gascoyne RD (2012) Pathogenesis of follicular lymphoma. J Clin Invest 122(10):3424-3431
39. Kuppers R (2009) The biology of Hodgkin's lymphoma. Nat Rev Cancer 9(1):15-27
40. Lenz G, Staudt LM (2010) Aggressive lymphomas. N Eng J Med 362(15):1417-1429. doi:10.10 56/NEJMra0807082; [pii] 362/15/1417
41. Lenz G, Wright G, Dave S, Kohlmann A, Xiao W, Powell J et al (2007) Gene expression signatures predict overall survival in diffuse large B cell lymphoma treated with Rit uximab and Chop-like chemotherapy. Blood 110(11):348 (ASH Annual Meeting Abstracts)
42. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher R I , Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313-2323. doi:10.1056/NEJMoa0802885 (L ymphoma/Leukemia Molecular Profiling P)
43. Lossos IS 2007i The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression Cancer Cell 12 3 189-191
44. Lossos IS, Levy R (2003) Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Sem Cancer Biol 13(3):191-202
45. Lukes RJ, Butler JJ (1966) The pathology and nomenclature of Hodgkin's disease. Cancer Res 26(6):1063-1083
46. Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2(7):465-475
47. MacLennan IC (1994) Germinal centers. Annu Rev Immunol 12:117-139
48. Manconi R, Poletti A, Volpe R, Sulfaro S, Carbone A (1988) Dendritic reticulum cell pattern as a microenvironmental indicator for a distinct origin of lymphoma of follicular mantle cells. Br J Haematol 68(2) :213-218
49. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444
50. Mariette X (2001) Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 60(11):1007-1010
51. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN et al (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103(5):1755-1762
52. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG et al (2003) Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102(3):996-999
53. Miyagaki T, Sugaya M, Suga H, Kamata M, Ohmatsu H, Fujita H et al (2011) IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 17(24):7529-7538
54. Morin RD, Johnson NA, Severson TM, M ungall AJ, An J, Goya R et al (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinalcenter origin. Nat Genet 42(2):181-185
55. Morin RD, Mendez-Lago M, Mun gall AJ, Goya R, Mungall KL, Corbett RD et al (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360):298-303
56. Nakasone ES, Askautrud HA, Kees T, Pa rk JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, Park J, Sinha P, Bissell MJ, Frengen E, Werb Z, Egeblad M (2012) Imaging tumorstroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21(4):488-503. doi:10.1016/j.ccr.2012.02.017
57. Nam-Cha SH, Roncador G, Sanchez-Verde L, Montes-Moreno S, Acevedo A, Dominguez-Franjo P et al (2008) PD-1, a follicular T-cell marker useful for recognizing nodular lymphocytepredominant Hodgkin lymphoma. Am J Surg Pathol 32(8):1252-1257
58. Nelson BH (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185(9):4977-4982. doi:10.4049/jimmunol.1001323
59. Nogai H, Dorken B, Lenz G (2011) Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 29(14):1803-1811. doi:10.1200/JCO.2010.33.3252
60. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471 (7337):189-195
61. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S (2013) Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 59(1):169-177
62. Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S et al (2007) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67(22):10703-10710
63. Poppema S (1989) The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol 135(2):351-357
64. Poppema S 2005 Immunobiology and pathophysiology of Hodgkin lymphomas Hematol Am Soc Hematol Educ Program 1 231-238
65. Poppema S, Delsol G , Pileri SA, Stein H (2008) Nodular lymphocyte predominant Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC , Lyon, pp 323-325
66. Reeder CB, Ansell SM (2011) Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 117(5):1453-1462. doi:10.1182/blood- 2010-06-255067
67. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, R osenwald A, Staudt LM, Grogan TM (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103(11):4251-4258. doi:10.1182/blood-2003-07-2365
68. Roberts RA, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM, Miller TP, Frutiger Y, Chan WC, Gascoyne RD, Ott G, Muller-Hermelink HK, Staudt LM, Rimsza LM (2006) Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 108(1):311-318. doi:10.1182/blood-2005-11-4742
69. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Sim on R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlan c M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25) :1937-1947. doi:10.1056/NEJMoa012914 (Lymphoma/Leukemia Molecular Profiling P
70. Sanchez-Aguilera A, Montalban C, de la Cueva P, Sanchez-Verde L, Morente MM, Garcia-Cosio M, Garcia-Larana J, Bellas C, Provencio M, Romagosa V, de Sevilla AF, Menarguez J, Sabin P, Mestre MJ, Mendez M, Fresno MF, Nicolas C, Piris MA, Garcia JF (2006) Tumor microenvironment and mitotic checkpoint are key factors in the out come of classic Hodgkin lymphoma. Blood 108(2):662-668. doi:10.1182/blood-2005-12-5125 (Spanish Hodgkin Lymphoma Study G
71. Sansonno D, De Vita S, Cornacchiulo V, Carbone A, Boiocchi M, Dammacco F (1996) Detection and distribution of hepatitis C virus-related proteins in lymph nodes of patients with type II mixed cryoglobulinemia and neoplastic or non-neoplastic lymphoproliferation. Blood 88(12):4638-4645
72. Sansonno D, Lauletta G, De Re V, Tucci FA, Gatti P, Racanelli V et al (2004) Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 34(1):126-136
73. Sansonno D, Carbone A, De Re V, Dammacco F (2007) Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology 46(4):572-578
74. Schmitz R, Stanelle J, Hansmann ML et al (2009) Pathogenesis of classical and lymphocytepredominant Hodgkin lymphoma. Annu Rev Pathol 4:151-174
75. Schneider P, Tschopp J (2003) BAFF and the regulation of B cell survival. Immunol Lett 88(1):57-62
76. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS et al (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 27(1):31-39
77. Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Stei d l C, Gascoyne RD (2013) Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 31(6):692-700. doi:10.1200/JCO.201 2.43.4589
78. Skibinski G, Skibinska A, James K (2001) The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs. Immunol 102(4):506-514
79. Smeltzer LP, Jones JM, Ziesmer S, Grote D, Yang ZZ, Novak A, Xiu B, Ristow K, Ansell SM (2013) Changes in the tumor microenvironment associated with transformation in follicula r lymphoma. J Clin Oncol 31:(suppl; abstr 8538
80. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T et al (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362(10):875-885
81. Steidl C, Connors JM, Gascoyne RD (2011) Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 29(14):1812-1826. doi:10.1200/JCO.2010.32.8401
82. Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES (2008) Classical Hodgkin lymphoma, introduction. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Piler i SA, Stein H et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 326-329
83. Talamini R, Montella M, Crovatto M, Dal Maso L, Crispo A, Negri E et al (2004) Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 110(3):380-385
84. Taneda S, Segerer S, Hudkins KL, Cui Y, Wen M, Segerer M et al (2001) Cryoglobulinemic glomerulonephritis in thymic stromal lymphopoietin transgenic mice. Am J Pathol 159(6):2355-2369
85. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Lepp a S (2007) A high tumorassociated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide- doxorubicin-vincristine-prednisone. Clin Cancer Res 13(19):5784-5789 . doi:10.1158/1078-0432.CCR-07-0778
86. Timens W, Visser L, Poppema S (1986) Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma. Lab Invest 54(4):457-461
87. Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S et al (2010) Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol 177(2):792-802
88. Weimar IS, de Jong D, Muller EJ, Nakamura T, van Gorp JM, de Gast GC et al (1997) Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to ex tracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 89(3):990-1000
89. Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES (1996) Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 87(11):4531-4537
90. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An internati onal phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22 (7):1622-1627. doi:10.1093/annonc/mdq626; [pii] mdq626
91. Woolf N (1998) Relation ship of neoplastic cells with their environment: tumor spread. In: Pathology basic and systemic. WB Sanders Company LTD, London, pp 249-260
92. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tash ima M et al (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111(6):3220-3224
93. Zignego AL, Gragnani L, Giannini C, Laffi G (2012) The hepatitis C virus infection as a systemic disease. Int Emerg Med 7(Suppl 3):S201-S208